Applicability of methylliberine as a salivary marker under postprandial conditions.

Toni Wildgrube, Nikolaus Alexander Link, Benno Ritucci, Michael Grimm, Stefan Engeli, Werner Weitschies, Philipp Schick

Abstract read

In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Toni WildgrubeDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Nikolaus Alexander LinkDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Benno RitucciDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Michael GrimmDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Stefan EngeliInstitute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Werner WeitschiesDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Philipp SchickDepartment of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary pharmacokinetics provide a non-invasive alternative to blood sampling and are widely applied for the investigation of formulation performance and physiological processes such as gastric emptying. In this context, caffeine is an established salivary marker due to its robust and well characterised pharmacokinetic behaviour and low susceptibility to postprandial physiological changes, allowing its use under both fasted and fed conditions. Recently, methylliberine has been introduced as a novel salivary marker and shown to be suitable for the assessment of gastric emptying under fasted conditions, offering advantages such as a short elimination half-life and simplified study designs as caffeine abstinence is unnecessary. However, its applicability as a salivary marker under postprandial conditions has not yet been evaluated. The present study aimed to assess whether methylliberine can be applied as a salivary marker under fed state conditions in a manner comparable to caffeine. Compression-coated tablets containing 100 mg methylliberine and 25 mg caffeine were developed to prevent oral contamination and characterised

Indexed as

CaffeineFed stateFood effectIn vivo studyMethylliberineSalivary analysis

Identifiers

PMID42370028

DOI10.1016/j.ijpx.2026.100584

PMCPMC13293696

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.